Kyprolis Launch Strength Shows Onyx Commercial Savvy
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx was able to tout the launch of two new products during its quarterly call. The company has been able to more than double expected sales for its solely-owned oncology drug, Kyprolis.